Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry.

ABSTRACT:

Background

Pazopanib is part of the therapeutic armamentarium for the treatment of patients with advanced non-adipocytic soft tissue sarcomas (STS) who have received prior chemotherapy, but its optimal use in STS histologies is still left to be further defined.

Design and methods

Data on STS patients treated with pazopanib in Italy have been prospectively collected from July 2013 to December 2019 through a drug monitoring registry managed by the Italian Medicines Agency (AIFA). This nationwide observational cohort study included patients with advanced STS who received pazopanib. Clinicians were mandatorily requested to fill in the AIFA monitoring registry in order to prescribe pazopanib. Patients were recorded on the basis of their clinical characteristics, histological subt

SUBMITTER: Vincenzi B 

PROVIDER: S-EPMC11635658 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature